Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subhashis Banerjee

Showing results (91-100 of 111) with videos related to

Pageof 12
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
The Journal of Biological Chemistry|July 31, 2020
Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restrictionSubhashis Banerjee, Sarbani Ghoshal, Joseph R Stevens, et al.
Nature|March 31, 2012
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonistsLaura A Solt, Yongjun Wang, Subhashis Banerjee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Rheumatology and Therapy|March 3, 2023
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid ArthritisPaul Emery, Yoshiya Tanaka, Vivian P Bykerk, et al.
The Journal of Dermatology|July 17, 2025
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized TrialJianzhong Zhang, Yangfeng Ding, Ping Wang, et al.
NPJ Aging and Mechanisms of Disease|August 31, 2021
Adropin correlates with aging-related neuropathology in humans and improves cognitive function in aging miceSubhashis Banerjee, Sarbani Ghoshal, Clemence Girardet, et al.
The Journal of Rheumatology|April 17, 2018
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb TrialMark C Genovese, César Pacheco-Tena, Arturo Covarrubias, et al.
European Journal of Medicinal Chemistry|July 8, 2023
Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915Carissa S Hampton, Sadichha Sitaula, Cyrielle Billon, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
Pageof 12

Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
The Journal of Biological Chemistry|July 31, 2020
Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restrictionSubhashis Banerjee, Sarbani Ghoshal, Joseph R Stevens, et al.
Nature|March 31, 2012
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonistsLaura A Solt, Yongjun Wang, Subhashis Banerjee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Rheumatology and Therapy|March 3, 2023
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid ArthritisPaul Emery, Yoshiya Tanaka, Vivian P Bykerk, et al.
The Journal of Dermatology|July 17, 2025
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized TrialJianzhong Zhang, Yangfeng Ding, Ping Wang, et al.
NPJ Aging and Mechanisms of Disease|August 31, 2021
Adropin correlates with aging-related neuropathology in humans and improves cognitive function in aging miceSubhashis Banerjee, Sarbani Ghoshal, Clemence Girardet, et al.
The Journal of Rheumatology|April 17, 2018
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb TrialMark C Genovese, César Pacheco-Tena, Arturo Covarrubias, et al.
European Journal of Medicinal Chemistry|July 8, 2023
Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915Carissa S Hampton, Sadichha Sitaula, Cyrielle Billon, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
Pageof 12